Arch Therapeutics Inc (NASDAQ:ARTH) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Thursday.

Other research analysts have also issued reports about the stock. HC Wainwright set a $3.00 target price on shares of Arch Therapeutics and gave the company a “buy” rating in a report on Thursday, July 27th. Zacks Investment Research upgraded shares of Arch Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. Finally, Ifs Securities restated an “outperform” rating on shares of Arch Therapeutics in a report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. Arch Therapeutics has a consensus rating of “Buy” and a consensus target price of $2.83.

Shares of Arch Therapeutics (ARTH) traded down 2.19053% during midday trading on Thursday, hitting $0.76175. 309,352 shares of the stock were exchanged. The firm has a 50-day moving average price of $0.80 and a 200 day moving average price of $0.63. Arch Therapeutics has a 12-month low of $0.41 and a 12-month high of $0.89. The firm’s market cap is $111.99 million.

ILLEGAL ACTIVITY WARNING: “Arch Therapeutics Inc (ARTH) Rating Lowered to Sell at ValuEngine” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at

About Arch Therapeutics

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Arch Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc and related companies with's FREE daily email newsletter.